Infectious adverse events related to endoscopic retrograde cholangiopancreatography (ERCP)
Executive Summary
Infectious adverse events occur in approximately 3% of patients undergoing Endoscopic Retrograde Cholangiopancreatography (ERCP). Acute cholangitis is the most prevalent of these complications, with a reported incidence of 1% to 3%. The pathogenesis of these infections typically involves the translocation of endogenous bacteria due to mucosal trauma or the introduction of bacteria into sterile spaces during contrast injection, particularly in the presence of biliary obstruction.
Key preventive strategies focus on targeted antibiotic prophylaxis for high-risk patients (e.g., those with anticipated incomplete drainage or hilar obstruction), meticulous endoscopic techniques to minimize hydrostatic pressure, and strict adherence to endoscope reprocessing protocols. Clinical suspicion of infection should be triggered by fever or abdominal pain occurring within 72 hours of the procedure. Management requires a combination of laboratory evaluation, diagnostic imaging, empiric antibiotic therapy, and, most critically, the establishment of effective biliary decompression.
Rates of Bacteremia and Infection
While severe infection is relatively rare, clinical data suggests the following:
Overall Infection Rate: Reported in up to 3% of all ERCP procedures.
Post-ERCP Cholangitis: In a study of over 4,000 patients, 2.4% developed cholangitis within 48 hours.
Transient Bacteremia: Occurs in approximately 18% of patients with biliary obstruction. While common, it often resolves without progressing to sepsis.
Pathogenesis and Microbiology
Infections following ERCP result from several primary mechanisms:
Bacterial Translocation: Mucosal trauma during the procedure can allow endogenous bacteria to enter the bloodstream.
Pressure-Induced Reflux: In patients with biliary obstruction, elevated biliary pressure—often exacerbated by the injection of contrast—can cause biliary-venous reflux.
Introduction of Contaminants: Contrast material may introduce bacteria into previously sterile spaces.
Microbial Profile: The most frequent causative organisms are enteric, gram-negative bacteria. While infected bile often contains polymicrobial flora, sepsis is typically associated with a single organism isolated in blood cultures.
Device-Related Transmission: Although rare, duodenoscopes have been implicated in the transmission of multidrug-resistant organisms, specifically carbapenem-resistant Enterobacteriaceae (CRE) such as E. coli and Klebsiella pneumoniae.
Preventive Strategies
Antibiotic Prophylaxis
Prophylaxis is not universal but is recommended for specific high-risk scenarios:
Incomplete Drainage: Anticipated inability to achieve full drainage (e.g., hilar biliary obstruction).
Specific Procedures: ERCP-guided cholangioscopy.
High-Risk Patients: Liver transplant recipients (due to immunosuppression and drainage complexity) and patients with primary sclerosing cholangitis (PSC).
Regimens: Common prophylactic agents include Ciprofloxacin, Amoxicillin-clavulanate, or Ampicillin plus Gentamicin.
Endoscopic Technical Considerations
Specific maneuvers during the procedure can mitigate infection risk:
Pressure Management: Aspirating bile before injecting contrast and using the minimum volume necessary for diagnostic imaging.
Drainage Verification: Assessing biliary stent patency immediately after placement by observing contrast flow and the presence of pneumobilia (air in the biliary tree).
Drainage Goals: The primary objective is to establish complete, long-term biliary drainage during the initial session. If a duct cannot be cleared of stones, a temporary plastic stent should be placed.
Equipment Reprocessing
Because duodenoscopes contact mucous membranes, they require high-level disinfection (HLD). While reusable scopes are the standard, disposable duodenoscopes are an alternative that may reduce infection risk, particularly for immunosuppressed patients, though their use is often limited by cost.
Clinical Evaluation and Initial Management
Recognition of Infection
Infection should be suspected if a patient presents with fever (>38°C), chills, or abdominal pain within 72 hours post-ERCP.
Diagnostic Workup
The initial evaluation includes:
Laboratory Testing: Complete blood count (CBC), electrolytes, liver biochemical/function tests, amylase, and lipase.
Cultures: Blood cultures must be obtained in febrile patients. If a repeat ERCP is performed, bile aspiration for culture is highly recommended, as it has a significantly higher diagnostic yield than blood cultures (97% vs. 32%).
Imaging: Abdominal ultrasound is often the first step to confirm pneumobilia (indicating stent patency) and rule out cholecystitis. Cross-sectional imaging (CT or MRI/MRCP) may also be used.
Empiric Management
Empiric antibiotics should be initiated promptly after cultures are drawn. Regimens must cover biliary flora, including streptococci, enterococci, Enterobacteriaceae, and Pseudomonas aeruginosa.
Specific Post-ERCP Infectious Adverse Events
Acute Cholangitis
The most common infectious event, typically presenting with Charcot's triad (fever, jaundice, and right upper quadrant pain). Severe (suppurative) cases may present with Reynold's pentad, adding hypotension and mental status changes.
Risk Factors: Hilar obstruction, incomplete stone clearance, history of PSC, and biopsy sampling during cholangioscopy (which increases bacteremia risk from 5% to 29%).
Severity Grading:
Mild: Temperature >38°C for 24–48 hours.
Moderate: Febrile/septic illness requiring >3 days of hospitalization or intervention.
Severe: Septic shock or requiring urgent procedural intervention.
Acute Cholecystitis
Occurs in 0.5% of cases. It is often caused by the introduction of nonsterile contrast into a poorly emptying gallbladder or the mechanical obstruction of the cystic duct by a self-expandable metal stent (SEMS).
Diagnosis: Suggested by RUQ tenderness and confirmed via imaging showing gallbladder wall thickening and pericholecystic fluid.
Management: Standard treatment includes antibiotics and cholecystectomy or nonsurgical drainage.
Other Rare Infections
Bacterial Peritonitis: Reported in 2.2% of patients with cirrhosis and ascites undergoing ERCP (compared to 1.1% for non-pancreaticobiliary endoscopy).
Acute Pancreatic Ductitis: A rare complication associated with pancreatic duct obstruction.
Reference Tables for Antimicrobial Intervention
Table 1: Prophylactic Regimens for High-Risk ERCP
Administered within 60–120 minutes prior to the procedure.
Table 2: Empiric Regimens for Suspected Post-ERCP Infection
Targeting healthcare-associated intra-abdominal pathogens.
